At present, there are no standard targeted therapies for the treatment of KRAS-mutated NSCLC, given that KRAS is still considered an “undruggable” protein whose inhibition is yet pharmacologically challenging [9,10]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.